MRSN

Mersana Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Retrieved on: 
Thursday, April 4, 2024
Spacecraft, MRSN, Employment, RSU, Cancer, Therapy

CAMBRIDGE, Mass., April 04, 2024 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced that on April 1, 2024, an authorized sub-committee of the Board of Directors of Mersana granted an inducement award, consisting of a restricted stock unit (RSU) award to acquire 35,100 shares of its common stock, to one new employee whose employment commenced in March 2024.

Key Points: 
  • CAMBRIDGE, Mass., April 04, 2024 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced that on April 1, 2024, an authorized sub-committee of the Board of Directors of Mersana granted an inducement award, consisting of a restricted stock unit (RSU) award to acquire 35,100 shares of its common stock, to one new employee whose employment commenced in March 2024.
  • The award was granted as an inducement material to the new employee entering employment with Mersana in accordance with Nasdaq Listing Rule 5635(c)(4).
  • The RSU award will vest in equal annual installments on the first four anniversaries of February 15, 2024, subject to the employee’s continued service with Mersana on each such vesting date.
  • The RSU award is subject to the terms and conditions of Mersana’s 2022 Inducement Stock Incentive Plan and the terms and conditions of an RSU agreement covering the grant.

Mersana Therapeutics Provides Business Update and Announces Fourth Quarter and Full Year 2023 Financial Results

Retrieved on: 
Wednesday, February 28, 2024
Conference call, Merck, Research, MRSN, GSK, Cancer, Food, B7-H4, Johnson & Johnson, Spacecraft, ESGO, ADC, Conference, HER2, Lifting, Therapy, Webcast, Patient, Congress, GSK plc, G&A, Merck Group, Pharmaceutical industry

Mersana plans to initiate tumor-specific expansion cohorts in the second quarter of 2024 and expects to share initial dose escalation and backfill cohort data in mid-2024.

Key Points: 
  • Mersana plans to initiate tumor-specific expansion cohorts in the second quarter of 2024 and expects to share initial dose escalation and backfill cohort data in mid-2024.
  • Collaboration revenue for the fourth quarter of 2023 was $10.7 million, compared to $14.7 million for the same period in 2022.
  • Included in the fourth quarter of 2023 G&A expenses were $1.9 million in non-cash stock-based compensation expenses.
  • ET to discuss business updates and its financial results for the fourth quarter and full year of 2023.

Mersana Therapeutics to Present at Upcoming Investor Conferences

Retrieved on: 
Tuesday, February 27, 2024
Cancer, Spacecraft, Therapy, MRSN

CAMBRIDGE, Mass., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced that members of management will present at the following upcoming investor conferences:

Key Points: 
  • CAMBRIDGE, Mass., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced that members of management will present at the following upcoming investor conferences:

Mersana Therapeutics to Host Fourth Quarter and Year End 2023 Conference Call on February 28, 2024

Retrieved on: 
Wednesday, February 21, 2024
Cancer, Spacecraft, Therapy, MRSN, Webcast

CAMBRIDGE, Mass., Feb. 21, 2024 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced that it will provide business updates and report its financial results for the fourth quarter and full year ended December 31, 2023 on Wednesday, February 28, 2024.

Key Points: 
  • CAMBRIDGE, Mass., Feb. 21, 2024 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced that it will provide business updates and report its financial results for the fourth quarter and full year ended December 31, 2023 on Wednesday, February 28, 2024.
  • The company will host a conference call and webcast at 8:00 a.m. Eastern Time that morning.
  • To access the call, please dial 877-270-2148 (domestic) or 412-902-6510 (international).
  • A live webcast of the presentation will be available on the Investors & Media section of the Mersana website at www.mersana.com , and a replay of the webcast will be available in the same location following the conference call for approximately 90 days.

Mersana Therapeutics to Participate in Guggenheim’s 6th Annual Biotechnology Conference

Retrieved on: 
Thursday, February 1, 2024
Spacecraft, Biotechnology, Cancer, Conference, Therapy, MRSN

CAMBRIDGE, Mass., Feb. 01, 2024 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced that members of management will participate in a fireside chat at Guggenheim’s 6th Annual Biotechnology Conference on February 8, 2024 at 11:30 a.m.

Key Points: 
  • CAMBRIDGE, Mass., Feb. 01, 2024 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced that members of management will participate in a fireside chat at Guggenheim’s 6th Annual Biotechnology Conference on February 8, 2024 at 11:30 a.m.
  • ET.
  • A live webcast of this event will be available on the Investors & Media section of Mersana’s website at www.mersana.com , and an archived replay will be available for approximately 90 days following the event.

Mersana Therapeutics Announces Business Updates, Expected 2024 Milestones and Upcoming Presentation at the 42nd Annual J.P. Morgan Healthcare Conference

Retrieved on: 
Friday, January 5, 2024
Conference, Merck Group, HER2, B7-H4, Spacecraft, GSK plc, Janssen, Therapy, MRSN, Motion, GSK, Pacific Time Zone, Cancer, Patient, ADC, Pharmaceutical industry

“Mersana’s next-generation ADC platforms are designed to overcome key limitations of traditional ADCs,” said Martin Huber, M.D., President and Chief Executive Officer of Mersana Therapeutics.

Key Points: 
  • “Mersana’s next-generation ADC platforms are designed to overcome key limitations of traditional ADCs,” said Martin Huber, M.D., President and Chief Executive Officer of Mersana Therapeutics.
  • “In 2024, we plan to demonstrate over several data presentations how Dolasynthen’s preclinical differentiation translates into the clinic.
  • These presentations will include initial clinical data from our ongoing Phase 1 clinical trial of XMT-1660.
  • Mersana President and CEO Dr. Martin Huber will present at the 42nd Annual J.P. Morgan Healthcare Conference on Thursday, January 11, 2024 at 2:15 p.m. Eastern Time/11:15 a.m. Pacific Time.

Mersana Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Retrieved on: 
Friday, December 1, 2023
MRSN, Spacecraft, Therapy, Cancer, Compensated emancipation, Employment, RSU, Pharmaceutical industry

CAMBRIDGE, Mass., Dec. 01, 2023 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced that on December 1, 2023, the Compensation Committee of the Board of Directors of Mersana granted an inducement award, consisting of a restricted stock unit (RSU) award to acquire 12,205 shares of its common stock, to one new employee whose employment commenced in November 2023.

Key Points: 
  • CAMBRIDGE, Mass., Dec. 01, 2023 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced that on December 1, 2023, the Compensation Committee of the Board of Directors of Mersana granted an inducement award, consisting of a restricted stock unit (RSU) award to acquire 12,205 shares of its common stock, to one new employee whose employment commenced in November 2023.
  • The award was granted as an inducement material to the new employee entering employment with Mersana in accordance with Nasdaq Listing Rule 5635(c)(4).
  • The RSU award will vest in equal annual installments on the first four anniversaries of November 15, 2023, subject to the employee’s continued service with Mersana on each such vesting date.
  • The RSU award is subject to the terms and conditions of Mersana’s 2022 Inducement Stock Incentive Plan and the terms and conditions of an RSU agreement covering the grant.

Mersana Therapeutics Provides Business Update and Announces Third Quarter 2023 Financial Results

Retrieved on: 
Tuesday, November 7, 2023
Research, ESMO, Food, DAR, HER2, Congress, G&A, Conference, European Society for Medical Oncology, R, B7-H4, ADC, Webcast, Cancer, Spacecraft, Merck Group, Oncology, GSK plc, GSK, Safety, Conference call, Therapy, Patient, Sodium-dependent phosphate transport protein 2B, Lifting, MRSN, Pharmaceutical industry, Fine chemical

ET

Key Points: 
  • ET
    CAMBRIDGE, Mass., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today provided a business update and reported financial results for the third quarter ended September 30, 2023.
  • In the third quarter of 2023, Mersana received $6 million in milestone payments from this agreement.
  • Mersana incurred $8.2 million in restructuring expenses for the third quarter of 2023 related primarily to severance-related costs and contract termination expenses.
  • ET to discuss business updates and its financial results for the third quarter of 2023.

Mersana Therapeutics to Host Third Quarter 2023 Conference Call on November 7, 2023

Retrieved on: 
Tuesday, October 31, 2023
Therapy, Webcast, Cancer, Spacecraft, MRSN, Fine chemical, Broadcasting

CAMBRIDGE, Mass., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced that it will provide business updates and report its financial results for the third quarter ended September 30, 2023 on Tuesday, November 7, 2023.

Key Points: 
  • CAMBRIDGE, Mass., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced that it will provide business updates and report its financial results for the third quarter ended September 30, 2023 on Tuesday, November 7, 2023.
  • The company will host a conference call and webcast at 8:00 a.m. Eastern Time that morning.
  • To access the call, please dial 877-270-2148 (domestic) or 412-902-6510 (international).
  • A live webcast of the presentation will be available on the Investors & Media section of the Mersana website at www.mersana.com , and a replay of the webcast will be available in the same location following the conference call for approximately 90 days.

Mersana Therapeutics Announces FDA has Lifted Clinical Hold on Phase 1 Clinical Trial of XMT-2056

Retrieved on: 
Tuesday, October 31, 2023
FDA, Stomach, Food, HER2, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, ADC, Spacecraft, Cancer, GSK plc, GSK, Safety, Therapy, Patient, Patient safety, Breast, MRSN, Pharmaceutical industry

“An in-depth analysis of cytokine, pharmacokinetic and other clinical data from patients enrolled in our Phase 1 trial indicated that XMT-2056 is a highly potent innate immune agonist,” said Martin Huber, M.D., President and Chief Executive Officer of Mersana Therapeutics.

Key Points: 
  • “An in-depth analysis of cytokine, pharmacokinetic and other clinical data from patients enrolled in our Phase 1 trial indicated that XMT-2056 is a highly potent innate immune agonist,” said Martin Huber, M.D., President and Chief Executive Officer of Mersana Therapeutics.
  • “Based on these data and with patient safety at the forefront of our efforts, we have lowered the starting dose in our Phase 1 dose escalation design.
  • The FDA has granted orphan drug designation to XMT-2056 for the treatment of gastric cancer.
  • In August 2022, Mersana entered into a global collaboration providing GSK plc with an exclusive option to co-develop and commercialize XMT-2056.